Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DMEPOS payments

This article was originally published in The Gray Sheet

Executive Summary

Health Care Financing Administration's Oct. 11 final rule governing claim submissions for durable medical equipment, prosthetics, orthotics and supplies becomes effective Dec. 11. Designed to prevent billing fraud, the rule requires DMEPOS suppliers to obtain a surety bond, and to certify with supplier standards. The rule, which HCFA originally proposed in January 1998 (1"The Gray Sheet" Jan. 26, 1998, I&W-4), carries a 60-day comment period

You may also be interested in...



HCFA Medicare DME supplier surety bond proposal has 15% "penal" level with $3 mil. ceiling.

MEDICARE DME SURETY BOND PROPOSAL: COMMENTS ON WAIVER IMPLEMENTATION are being sought by the Health Care Financing Administration in a Jan. 20 Federal Register proposed rule. Under the proposal, HCFA would not immediately implement the waiver, citing a lack of time between enactment of the Balanced Budget Act and the Jan. 1, 1998 effective date of the requirement.

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel